Navigation Links
Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
Date:8/1/2013

BUFFALO, N.Y., Aug. 1, 2013 /PRNewswire/ -- Kinex Pharmaceuticals is pleased to announce that their application for the Small Entrepreneur Research Assistance Programme has been approved by the Innovation and Technology Commission of Hong Kong.  This financial support will be used to fund Kinex's development of preclinical data on both docetaxel (Taxotere) and doxorubicin (Doxil) when combined with HM30181A, an innovative P-glycoprotein pump inhibitor that converts IV drugs into oral formulations.  Additionally, it will provide the opportunity to work with key opinion leaders in Hong Kong as well as some of the foremost clinics and institutions.  These efforts will further broaden the Orascovery program and is expected to significantly increase Kinex's pipeline portfolio.

The Orascovery program is based on an important platform technology currently co-developed by Hanmi Pharmaceuticals and Kinex, compound HM30181A, a potent and selective P-glycoprotein (PGP) pump inhibitor.  Suppression of the PGP pump allows certain clinically important compounds (such as Paclitaxel and Irinotecan, among others) which would normally be effluxed back into the gastrointestinal tract and excreted, to enter the bloodstream and be bioavailable through oral administration.  Importantly, HM30181A is a very effective PGP inhibitor that is not systemically absorbed.

The Orascovery technology has led to the initiation of clinical trials being conducted with both an oral formulation of paclitaxel (Oraxol), currently in Phase II clinical trials in Korea, and an oral formulation of Irinotecan (Oratecan), which has completed a Phase I clinical trial in Korea. On July 22, Kinex announced that the US FDA had allowed the company's IND for Oraxol.  Trials will begin this fall.

In May of 2013, Kinex licensed the Oraxol and Oratecan rights for Australia and '/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
2. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
3. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
4. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
5. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
6. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
7. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
8. Kinex Pharmaceuticals Receives Substantial Strategic Investment
9. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
10. Avion Pharmaceuticals, LLC, receives top accolades for trade and marketing achievements at the 11th Annual American Business Awards (The "Stevie Awards")
11. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 ... put the brakes on motherhood. And for many young women, ... new research suggests. Women in their early 20s appear ... tough economic times. But, according to the new study, that ... 40s and beyond. The findings suggest that higher unemployment ...
(Date:9/30/2014)... "brain tsunamis" in injured patients without opening the ... thanks to pioneering research at the University of ... led by Jed Hartings, PhD, research associate professor ... College of Medicine, has shown that spreading depolarizationselectrical ... tsunami wavescan be measured by the placement of ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Sleep apnea is a potential health ... to a possible culprit behind the disorder: a "fat" tongue. ... deposits are increased in the tongue of obese patients with ... of the Sleep Center at the University of Pennsylvania Medical ... which will publish the findings Oct. 1. Sleep apnea ...
(Date:9/30/2014)... stranger to the children of Tanzania. What is rare ... services, including reliable diagnosis and evidence-based treatments. There is ... in Swahili, a major language of the region. In ... and the University of Georgia (UGA) describe a culturally ... in the country and found to be effective for ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling costs ... treat Medicare patients has had no meaningful impact on ... in the Journal of Clinical Oncology published ... chemotherapy to treat colorectal and lung cancers, and did ... those drugs following the implementation of the recent Medicare ...
Breaking Medicine News(10 mins):Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2
... food products. According to a team of University of ... on its viewers, especially university students. , "The transition ... a time for taking on many negative health behaviors ... in physical activity and fruit and vegetable consumption," said ...
... common vaginal infection may make women more susceptible to contracting ... at Chapel Hill School of Public Health researchers have found. ... more than 30,700 women from around the world, showed that ... vaginosis in women of reproductive age were more likely ...
... standardization across ... savings, IRVINE, Calif., July 31 Masimo, ... that Aurora Health Care has completed a system-wide,conversion ... health,care provider with 13 hospitals and more than ...
... support nonprofits in Portland and Seattle that improve health ... ... 31 The Regence Foundation today,announced three grants totaling $195,000 for ... Regence,Foundation is the corporate foundation of The Regence Group and was ...
... and health systems,expert Ann Lion Coleman will join ... project in August 2008. Health Systems 20/20 is ... to strengthen health,systems by using an integrated approach ... to further the use of,life-saving priority health services., ...
... July 31 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... Western,healthcare products and services in the People,s Republic ... its fiscal 2009 first quarter,financial results on Thursday, ... host a conference call at 8:00 am ET ...
Cached Medicine News:Health News:Watching too much TV is causing some university students to pack on the pounds 2Health News:UNC study: Common vaginal infection may increase risk of HIV infection 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 5Health News:Regence Foundation Announces Three Grants Totaling $195,000 2Health News:Ann Lion Coleman Joins Abt Associates to Direct USAID Health Systems 20/20 Project 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 3
... , Standby: A standby switch maintains power to ... 1 s (1 pulse/s) , Tetanus: 100 ... s) , Output Current: Adjustable from 0-70 mA ... (200-us duration) , Indicators: Battery LED (green) indicates ...
... A range of easy to use ... RDG nerve locator, peripheral nerve stimulator, and ... insulating pole, plastic hub, and pencil point ... an inexpensive, practical and easy to use ...
Based on the original MS-1 design the new MS-1B includes low battery detection, FET based output circuitry and enhanced battery compartment....
... for the delivery and monitoring of inhaled ... is a fully integrated, innovative instrument used ... therapy. The INOvent delivery system works in ... machine) to deliver a constant concentration of ...
Medicine Products: